GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Cyclically Adjusted Price-to-FCF

Prothena (Prothena) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Prothena Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Prothena's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Cyclically Adjusted Price-to-FCF Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prothena Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prothena's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Prothena's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Prothena's Cyclically Adjusted Price-to-FCF falls into.



Prothena Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Prothena's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Prothena's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.362/120.9901*120.9901
=-1.362

Current CPI (Mar. 2024) = 120.9901.

Prothena Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.257 100.773 0.309
201409 -0.452 100.474 -0.544
201412 -0.459 99.576 -0.558
201503 -0.538 99.975 -0.651
201506 -0.363 100.573 -0.437
201509 -0.548 100.274 -0.661
201512 -0.532 99.676 -0.646
201603 -0.743 99.676 -0.902
201606 -0.816 101.072 -0.977
201609 -1.122 100.274 -1.354
201612 -1.183 99.676 -1.436
201703 -1.128 100.374 -1.360
201706 -0.953 100.673 -1.145
201709 -0.477 100.474 -0.574
201712 -1.037 100.075 -1.254
201803 -0.821 100.573 -0.988
201806 1.457 101.072 1.744
201809 -0.846 101.371 -1.010
201812 -0.567 100.773 -0.681
201903 -0.441 101.670 -0.525
201906 -0.305 102.168 -0.361
201909 -0.230 102.268 -0.272
201912 -0.366 102.068 -0.434
202003 -0.581 102.367 -0.687
202006 -0.470 101.769 -0.559
202009 -0.488 101.072 -0.584
202012 -0.480 101.072 -0.575
202103 -0.838 102.367 -0.990
202106 0.772 103.364 0.904
202109 2.185 104.859 2.521
202112 -0.436 106.653 -0.495
202203 -0.802 109.245 -0.888
202206 -0.757 112.779 -0.812
202209 -0.666 113.504 -0.710
202212 -0.105 115.436 -0.110
202303 -0.905 117.609 -0.931
202306 -0.860 119.662 -0.870
202309 0.156 120.749 0.156
202312 -0.980 120.749 -0.982
202403 -1.362 120.990 -1.362

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Prothena  (NAS:PRTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Prothena Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Prothena's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena (Prothena) Business Description

Industry
Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453